BARCELONA — In a first test of Scorpion Therapeutics’ therapy for breast cancer and other solid tumors, a small ...
Incyte said it has positive late-phase results for its PD-1 drug Zynyz in certain patients with squamous cell carcinoma, ...
Nuvation Bio outlined pooled data from its two Phase 2 studies at the annual European Society for Medical Oncology confab in ...
GSK and iTeos have unveiled positive mid-phase data for their PD-1 plus TIGIT doublet in certain lung cancer patients, ...
The SEC’s investigation into the $8 billion deal between Grail and Illumina is examining sales forecasts made by Grail’s ...
An FDA advisory committee recommended against full approval for Alfasigma and Intercept Pharmaceuticals’ rare liver disease ...
Arbor Biotechnologies is trimming its early-stage discovery work, leading to layoffs in the group. The move was confirmed by an Arbor spokesperson, with CEO Devyn Smith saying in a statement to ...
The rise and fall of the short-lived biotech Zymergen has ended with a $30 million penalty from the SEC. Zymergen's rise ...
One of my distinct memories of the early pandemic was sitting in Moderna CEO Stéphane Bancel’s office in Cambridge, MA, as he ...
Viral disease-focused biotech Atea Pharmaceuticals announced a late-stage trial failure for its nucleotide polymerase ...
The FDA on Friday approved a new formulation of Roche and Genentech’s multiple sclerosis drug Ocrevus in what they hope will ...
Aurinia Pharmaceuticals offered an olive branch to a group of shareholders clamoring for change. It's shrinking its board by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback